10-Q: TAO Synergies Pivots to AI Crypto, Reports Q3 Loss

TAO Synergies Inc. reports a significant net loss for Q3 2025, driven by its pivot to an AI crypto treasury strategy and related expenses, while discontinuing prior drug development programs.

Summary

• TAO Synergies Inc. (formerly Synaptogenix, Inc.) has fully transitioned its business strategy from biopharmaceutical drug development to a cryptocurrency treasury strategy focused on TAO, the native token of Bittensor, a decentralized AI blockchain network.
• The company launched 'The TAO Daily,' a media, news, and insight platform dedicated to the Bittensor ecosystem, and engaged prominent advisors Joseph Jacks and James Altucher for its digital asset treasury strategy.
• A net loss of $(3,923,247) was reported for the three months ended September 30, 2025, compared to $(5,742,013) for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss significantly increased to $(21,054,156) from $(7,222,021) in the prior year.
• Revenue from TAO staking was $203,371 for the three months and $207,333 for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased substantially from $17,656,221 at December 31, 2024, to $1,445,427 at September 30, 2025.
• Digital assets (TAO) held were valued at $15,381,039 at September 30, 2025, with an unrealized loss of $(2,396,497) for the nine months.
• Total cash and TAO value combined was approximately $34 million as of November 11, 2025.
• The company completed a Series D Private Placement, raising $4,924,000, and a Series E Preferred Stock Financing on October 15, 2025, involving 11,000 shares of Series E preferred stock and warrants for 1,375,000 shares of Common Stock.
• The Series C Preferred Stock has been completely redeemed, and the MS clinical trial with Cleveland Clinic was terminated due to slow enrollment.

Sentiment

Score: 4

Explanation: While the company has a clear new strategic direction and has raised capital, the significant increase in net loss, substantial decrease in cash, and unrealized losses on digital assets indicate considerable financial challenges and risks associated with the new strategy. The discontinuation of drug trials also marks a significant shift away from previous core activities.

Positives

• Successfully pivoted to a cryptocurrency treasury strategy focused on the AI crypto coin TAO, aiming for revenue generation and capital appreciation.
• Generated initial revenue from TAO staking: $203,371 for the three months and $207,333 for the nine months ended September 30, 2025.
• Launched 'The TAO Daily' media platform, expanding into the digital asset information space.
• Engaged prominent advisors Joseph Jacks and James Altucher for the digital asset treasury strategy.
• Successfully raised capital through a Series D Private Placement ($4,924,000) and a Series E Preferred Stock Financing (11,000 shares of Series E preferred stock and warrants for 1,375,000 shares of Common Stock).
• Combined cash and digital assets total approximately $34 million as of November 11, 2025, which is expected to support operations for at least the next 12 months.
• Net loss decreased for the three months ended September 30, 2025, compared to the same period in 2024.

Negatives

• Reported a significant net loss of $(21,054,156) for the nine months ended September 30, 2025, a substantial increase from $(7,222,021) in the prior year.
• Cash and cash equivalents decreased significantly from $17,656,221 at December 31, 2024, to $1,445,427 at September 30, 2025.
• Incurred a substantial unrealized loss on digital assets of $(2,396,497) for the nine months ended September 30, 2025.
• General and administrative expenses increased by 43.5% for the nine months ended September 30, 2025, primarily due to legal fees, outside operations consulting services (including non-cash warrant expenses for crypto experts), and stock options compensation.
• Discontinued the MS clinical trial with Cleveland Clinic due to slow enrollment, indicating a setback in previous biopharmaceutical endeavors.
• Other expenses, net, increased significantly to $(15,149,658) for the nine months ended September 30, 2025, largely due to unrealized losses on digital assets and changes in fair value of warrant and derivative liabilities.
• Operating cash flow remains negative, with $3,944,213 used in operating activities for the nine months ended September 30, 2025.
• The company expects to need additional capital to continue pursuing its TAO treasury strategy, indicating ongoing funding needs.
• Management concluded that disclosure controls and procedures are not effective due to inadequate segregation of duties, ineffective processes over period-end financial disclosure and reporting, and ineffective IT general computing controls.

Risks

• Ownership and operation of 'The TAO Daily' may create perceived or actual conflicts of interest due to substantial financial interests in TAO, potentially influencing trading prices and damaging reputation.
• Risk of insider trading allegations or market manipulation claims if material non-public information is inadvertently shared or leveraged by 'The TAO Daily'.
• The company's strategy to prioritize long-term interests may not maximize short-term or medium-term financial results, potentially leading to shareholder dissatisfaction.
• Dependence on reliable performance and increasing capabilities of technical and data infrastructure; failure to maintain or protect systems could damage reputation, lead to user loss, fines, and civil liability.
• Significant exposure to security incidents, cyberattacks, human error, fraud, or malice, which could disrupt services, lead to data breaches, intellectual property theft, and substantial costs not fully covered by insurance.
• Failure to comply with evolving data protection laws and regulations (e.g., HIPAA, GDPR) could result in government enforcement actions, private litigation, significant fines, and adverse publicity.
• Reliance on continued and unimpeded access to the internet and third-party cloud-based hosting services; disruptions could interrupt services and harm operations.
• Advertising revenues from 'The TAO Daily' are sensitive to macroeconomic conditions, competition from large digital platforms, and evolving digital advertising trends and regulations.
• Operating results are heavily dependent on the price of TAO, which is highly volatile and subject to sharp declines, market manipulation, and speculative investor behavior.
• Concentration of TAO holdings among a small number of parties increases the risk of outsized influence over governance and market stability.
• Accurately valuing crypto assets like TAO is challenging due to global trading across numerous, often unregulated, exchanges, leading to price volatility and disparities.
• Bittensor network faces significant technical, operational, scalability, governance, and regulatory risks, including dependence on off-chain infrastructure, potential vulnerabilities in AI validation, and decentralized governance inefficiencies.
• The Subtensor blockchain's proof-of-authority model centralizes transaction ordering and finality, increasing the risk of network halts, delayed processing, or selective censorship.
• Open-source and decentralized design of crypto asset networks exposes the company to risks related to forks, air drops, and incidental rights, which can create new assets, lead to technical challenges, unexpected tax liabilities, or regulatory scrutiny.
• Reliance on BitGo Prime LLC and BitGo Trust Company, Inc. for trading, custody, and settlement of TAO exposes the company to risks of technical failures, operational errors, cyber-attacks, and limited liability from the custodians (e.g., $5,000 cap for Yuma agreement).
• Lack of FDIC/SIPC insurance for digital assets held by the custodian, and limited insurance coverage, means assets may not be fully protected against losses or in the event of custodian insolvency.
• Staking activities involve significant risks, including borrower default, operational failures, and potential loss of TAO, with limited recourse for missed rewards (e.g., Yuma agreement caps liability at $5,000).
• Regulatory uncertainty surrounding the classification of crypto assets as securities could subject the company to extensive regulatory burdens, registration requirements, and enforcement actions, potentially forcing it to alter or cease operations.

Future Outlook

The company expects its current cash and TAO token market value, approximately $34 million as of November 11, 2025, to be sufficient to support projected operating requirements and financial commitments for at least the next 12 months. This includes continuing to increase TAO holdings and staking while determining the strategy for Bryostatin-1. Additional capital is expected to be needed to further pursue the TAO treasury strategy. The company may explore additional yield-enhancement strategies, such as participation in TAO subnets, potentially with third-party partners. Stockholder approval for Series E Preferred Stock issuance matters will be sought by December 31, 2025, and a resale registration statement for Series E securities will be filed and maintained.

Management Comments

• Our Board has adopted a long-only TAO accumulation policy under which we allocate substantial portions of our excess cash to purchase TAO with the objective of maximizing tokens per share.
• We seek to stake TAO for revenue generation and capital appreciation, a strategy that underscores our mission to create significant value for shareholders.
• We expect that our current cash and cash equivalents and TAO token market value, approximately $34 million as of the date of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next 12 months from the date of this Quarterly Report.
• We expect to need additional capital in order to continue pursuing its TAO treasury strategy.
• We are currently evaluating our plans to advance Fragile X development.
• We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.

Industry Context

The company's pivot from biopharmaceuticals to an AI crypto treasury strategy aligns with the growing interest and investment in artificial intelligence and blockchain technologies. The focus on TAO, the native cryptocurrency of Bittensor, positions the company within the decentralized AI sector, a niche but rapidly evolving area. The launch of 'The TAO Daily' indicates an attempt to establish a media presence and thought leadership within the Bittensor ecosystem, leveraging the growing demand for information in this space. The engagement of crypto experts reflects the specialized knowledge required in this emerging industry. The significant volatility of crypto assets, as highlighted in the risk factors, is a characteristic of the broader cryptoeconomy, which has seen steep increases and declines in value. Regulatory uncertainty surrounding crypto assets is a pervasive industry trend, impacting how companies operate and how assets are classified.

Management Changes

Corporate Governance

Related Party Transactions

• SM Capital Management, LLC (SMCM), owned and controlled by Joshua N. Silverman (Executive Chairman), had a consulting agreement with an annual fee of $120,000, which was superseded by the Silverman Compensation Agreement on August 14, 2025.
• Joshua N. Silverman, Executive Chairman, received a salary of $30,000 per month from June 6, 2025, and subsequently entered into an Executive Compensation Agreement effective July 1, 2025, with an annual base salary of $360,000.
• Dr. Daniel L. Alkon, after resigning as an officer/director/CSO, entered into a consulting agreement on June 4, 2025, with a base monthly salary reduced to $12,500, and further reduced to $1,500 on August 9, 2025. He is eligible for incentive fees related to Bryostatin asset transactions.
• The company has a Technology License and Services Agreement (CRE License Agreement) with Cognitive Research Enterprises, Inc. (CRE), a related party, but no statements of work agreements were entered into during the nine months ended September 30, 2025 and 2024.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity financing and high volatility of TAO price, which directly impacts asset value. The strategic pivot introduces new risks and opportunities, while increased net loss and decreased cash flow are negative.
• Employees are impacted by management changes and compensation adjustments, reflecting the company's restructuring and new strategic focus.
• Customers of 'The TAO Daily' may perceive bias due to the company's financial interest in TAO, potentially affecting the platform's credibility and reliance on its information.
• Creditors are exposed to the company's financial commitments, including redemption requirements and dividends on Series D and Series E Preferred Stock.
• Consultants, such as Joseph Jacks and James Altucher, have received warrants for their services, aligning their interests with the company's crypto strategy and potentially influencing its direction.

Next Steps

• Continue allocating substantial portions of excess cash to TAO.
• Continue staking TAO for revenue generation and capital appreciation.
• Evaluate production alternatives for synthetic bryostatin.
• Determine how to proceed with current development programs for Bryostatin-1.
• Evaluate plans to advance Fragile X development (IND on clinical hold).
• Explore additional yield-enhancement strategies, including participation in TAO subnets.
• Seek stockholder approval for Series E Preferred Stock issuance matters at a meeting no later than December 31, 2025.
• File a resale registration statement for Series E securities promptly and maintain its effectiveness.
• Implement new controls associated with its cryptocurrency treasury strategy, including procedures for third-party vendors and management tools for monitoring cash, investment, equity transactions, and fair value of digital assets.

Key Dates

Recommendation

The company is undergoing a significant and high-risk strategic pivot from biopharmaceuticals to an AI crypto treasury strategy. While the new direction offers potential for growth in an emerging sector, it comes with substantial financial losses, cash burn, and exposure to extreme market volatility and regulatory uncertainty inherent in crypto assets. The recent capital raises provide some liquidity, but the need for additional capital is anticipated. The internal control weaknesses also present a concern. A 'Hold' recommendation reflects the speculative nature of the new strategy, acknowledging both the potential upside if the crypto strategy succeeds and the significant downside risks and current financial challenges. Investors should monitor the execution of the crypto strategy, TAO price performance, and regulatory developments closely.

Keywords

TAO Synergies Inc., TAOX, Cryptocurrency, AI Crypto, Bittensor, TAO token, Blockchain, Digital Assets, Staking, Financial Results, SEC Filing, 10-Q, Quarterly Report, Biopharmaceutical, Neurodegenerative Diseases, Bryostatin-1, Corporate Strategy, Capital Raise, Warrants, Preferred Stock, Consulting Agreement, Risk Factors, The TAO Daily, Proof-of-Intelligence, Custodial Services, BitGo